drugset / Trial / NCT00324649
Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada
RandomizedParallel-groupOpen-labelTreatment
Summary
This study evaluated changes in body fat distribution in human immunodeficiency virus type 1 (HIV-1) infected participants who either switched from a zidovudine- plus lamivudine- containing highly active antiretroviral therapy (HAART) regimen to a regimen containing Truvada® (a fixed-dose combination tablet of emtricitabine \[FTC, 200 mg\] and tenofovir disoproxil fumarate \[TDF, 300 mg\]) or who remained on a zidovudine- plus lamivudine-containing regimen. Subjects continued their protease inhibitor (PI) or nonnucleoside reverse transcriptase inhibitor (NNRTI).
Timeline
- Start
- 2006-05
- Primary completion
- 2008-03
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lamivudine | Other / unclassified | — | — |
| Subject | Tenofovir disoproxil fumarate | Small molecule | 300 mg | — |
| Comparator | Zidovudine | Small molecule | — | — |
| Subject | emtricitabine | Other / unclassified | 200 mg | — |
Indications
No indication recorded.